# A Study for Patients Who Completed VITALITY-ALS (CY 4031)

> **NCT02936635** · PHASE3 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 280 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** tirasemtiv

## Key facts

- **NCT ID:** NCT02936635
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-17
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-10-26
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936635, "A Study for Patients Who Completed VITALITY-ALS (CY 4031)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02936635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*